AVITA Medical slashes Q4 2024 revenue outlook to ~$18.4M; profitability pushed to Q4 2025

AVITA Medical, Inc.

2024-FY EPS reported -$2.39 revenue$64,251,000

Q4 2024 commercial revenue expected ~$18.4M (30% YoY growth) vs prior guidance of $22.3-24.3M.
Full-year 2024 revenue now ~$64.3M (29% YoY growth) vs prior $68-70M.
FY 2025 revenue guidance $100-106M (55-65% growth).
Cashflow breakeven and GAAP profitability now expected in Q4 2025, delayed from Q3 2025.
Miss attributed to slower hospital year-end purchasing; new products RECELL GO and Cohealyx remain growth drivers.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.